Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19322628 | CAPSID VARIANTS AND METHODS OF USING THE SAME | September 2025 | February 2026 | Allow | 5 | 1 | 0 | No | No |
| 19209113 | CAPSID VARIANTS AND METHODS OF USING THE SAME | May 2025 | November 2025 | Allow | 6 | 1 | 0 | No | No |
| 18748995 | NOVEL TREATMENT REGIMEN FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | June 2024 | October 2025 | Allow | 16 | 2 | 1 | No | No |
| 18599308 | TREATMENT REGIMEN FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | March 2024 | November 2025 | Allow | 20 | 1 | 0 | No | No |
| 18443314 | MICROPOROUS ANNEALED PARTICLE GEL SYSTEM | February 2024 | November 2025 | Allow | 21 | 1 | 1 | No | No |
| 18390486 | BROADLY NEUTRALIZING ANTI-HIV-1 ANTIBODIES AND METHODS OF USE THEREOF | December 2023 | July 2025 | Allow | 19 | 2 | 1 | Yes | No |
| 18533676 | Therapeutic Vaccine for Hepatitis B Virus (HBV) using the HBV Core Antigen | December 2023 | August 2025 | Allow | 20 | 1 | 1 | No | No |
| 18526015 | CORONAVIRUS VACCINE FORMULATIONS | December 2023 | June 2025 | Allow | 18 | 1 | 1 | No | No |
| 18479761 | METHODS OF REDOSING GENE THERAPY VECTORS | October 2023 | December 2025 | Abandon | 27 | 0 | 1 | No | No |
| 18364884 | EGG ALLERGY ANTIGEN | August 2023 | October 2025 | Allow | 27 | 1 | 2 | No | No |
| 18336409 | Compositions and Methods for Treating Retinal Disorders | June 2023 | July 2025 | Allow | 25 | 1 | 1 | No | No |
| 18206249 | HBV VACCINE | June 2023 | September 2025 | Allow | 27 | 2 | 1 | No | No |
| 18314490 | BROADLY NEUTRALIZING ANTIBODIES AGAINST HIV | May 2023 | May 2025 | Allow | 24 | 1 | 1 | No | No |
| 18022488 | CIRCULAR RNA VACCINES AND METHODS OF USE THEREOF | February 2023 | March 2026 | Allow | 37 | 1 | 0 | No | No |
| 18164988 | HIV-1 ENV FUSION PEPTIDE IMMUNOGENS AND THEIR USE | February 2023 | July 2025 | Allow | 29 | 2 | 1 | No | No |
| 18164942 | RECOMBINANT AAV1, AAV5, AND AAV6 CAPSID MUTANTS AND USES THEREOF | February 2023 | November 2025 | Abandon | 34 | 2 | 1 | No | No |
| 18005027 | Method for the Production of AAV | January 2023 | January 2026 | Allow | 36 | 2 | 0 | No | No |
| 18067508 | RAPID VERIFICATION OF VIRUS PARTICLE PRODUCTION FOR A PERSONALIZED VACCINE | December 2022 | October 2025 | Allow | 34 | 1 | 0 | No | No |
| 18061831 | CORONAVIRUS VACCINE FORMULATIONS | December 2022 | April 2025 | Allow | 29 | 2 | 1 | No | No |
| 18000651 | MULTIMERIC IMMUNOMODULATOR TARGETING 4-1BB | December 2022 | February 2026 | Abandon | 38 | 0 | 1 | No | No |
| 17926444 | MRNA OR MRNA COMPOSITION, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | November 2022 | March 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17997996 | MEANS AND METHODS FOR DETECTING NOVEL CORONAVIRUS (SARS-COV-2) | November 2022 | March 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17996879 | FOOT-AND-MOUTH DISEASE VIRUS-LIKE PARTICLE ANTIGEN, VACCINE COMPOSITION, PREPARATION METHOD, AND USE THEREOF | October 2022 | February 2026 | Allow | 40 | 1 | 1 | Yes | No |
| 17907576 | DETECTION OF LOW ABUNDANCE VIRUSES | September 2022 | February 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17909777 | Conditions Improving Poxvirus Stability | September 2022 | February 2026 | Allow | 41 | 1 | 1 | No | No |
| 17759803 | Compositions and Methods for Preventing and Treating Coronavirus Infection - Sars-Cov-2 Vaccines | July 2022 | December 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17795181 | T CELL EPITOPES AND RELATED COMPOSITIONS USEFUL IN THE PREVENTION, DIAGNOSIS, AND TREATMENT OF COVID-19 | July 2022 | January 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17865257 | Transient Expression of Biologic Materials | July 2022 | November 2025 | Allow | 40 | 1 | 1 | No | No |
| 17757303 | RNA NANOPARTICLE FOR LIVER CANCER TREATMENT | June 2022 | February 2026 | Allow | 44 | 2 | 1 | No | No |
| 17782366 | POPTAG PEPTIDE AND USES THEREOF | June 2022 | March 2026 | Allow | 45 | 1 | 1 | Yes | No |
| 17733719 | Compositions and Methods for Multiplex Detection of Microorganisms Using Peptide-Tagged Recombinant Infectious Agents | April 2022 | March 2026 | Abandon | 46 | 1 | 1 | No | No |
| 17729375 | COMPOSITIONS FOR THE TREATMENT OF DISEASE | April 2022 | October 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17657296 | EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES | March 2022 | November 2025 | Allow | 43 | 3 | 1 | No | No |
| 17573529 | COMPOSITIONS AND METHODS OF USING A DNA NANOSWITCH FOR THE DETECTION OF RNA | January 2022 | February 2026 | Abandon | 49 | 1 | 1 | No | No |
| 17458812 | Methods and Compositions for the Detection of Host Protein Cleavage by Group IV Viral Proteases | August 2021 | March 2026 | Allow | 55 | 1 | 1 | No | No |
| 17386289 | NANOPARTICLE VACCINES WITH NOVEL STRUCTURAL COMPONENTS | July 2021 | September 2025 | Allow | 49 | 1 | 1 | Yes | No |
| 17420002 | PEPTIDE IMMUNOGENS TARGETING CALCITONIN GENE-RELATED PEPTIDE (CGRP) AND FORMULATIONS THEREOF FOR PREVENTION AND TREATMENT OF MIGRAINE | June 2021 | February 2026 | Allow | 55 | 2 | 1 | Yes | No |
| 17418977 | POLYMERIC NANOVACCINES AND USES THEREOF | June 2021 | October 2025 | Allow | 52 | 2 | 1 | No | No |
| 17294016 | HIGH-AFFINITY TCR FOR AFP RECOGNITION | May 2021 | September 2025 | Allow | 52 | 1 | 1 | No | No |
| 17220647 | Methods and Systems for Detection of Pathogens | April 2021 | September 2025 | Allow | 53 | 4 | 1 | No | No |
| 17218930 | METHODS AND COMPOSITIONS FOR DETECTING CO-INFECTION WITH SARS-COV-2 AND INFLUENZA A VIRUS AND/OR INFLUENZA B VIRUS | March 2021 | February 2025 | Abandon | 46 | 2 | 2 | Yes | No |
| 17249071 | COMPOSITIONS, KITS AND METHODS FOR DETECTION OF VIRAL SEQUENCES | February 2021 | March 2025 | Allow | 49 | 2 | 1 | No | No |
| 17052478 | USE OF BETA-GLUCAN EXTRACT IN THE IMMUNOPOTENTIATION OF AN AVIAN ANIMAL | November 2020 | February 2026 | Allow | 60 | 8 | 1 | Yes | No |
| 17050946 | SYNTHETIC CHIMERIC VACCINIA VIRUS | October 2020 | October 2025 | Allow | 59 | 3 | 1 | No | No |
| 17034168 | METHOD FOR LARGE-SCALE PREPARATION OF PURIFIED PREPARATION OF RECOMBINANT LENTIVIRAL VECTOR AT GMP GRADE | September 2020 | November 2025 | Allow | 60 | 4 | 1 | No | No |
| 16980341 | METHODS FOR TREATING HPV-ASSOCIATED DISEASES | September 2020 | December 2025 | Allow | 60 | 4 | 1 | No | No |
| 16145848 | METHOD OF DETECTING AND/OR IDENTIFYING ADENO-ASSOCIATED VIRUS (AAV) SEQUENCES AND ISOLATING NOVEL SEQUENCES IDENTIFIED THEREBY | September 2018 | November 2019 | Allow | 13 | 1 | 1 | Yes | No |
| 15964198 | ANTIGENS AND VACCINES DIRECTED AGAINST HUMAN ENTEROVIRUSES | April 2018 | September 2019 | Allow | 17 | 1 | 1 | Yes | No |
| 15964211 | ANTIGENS AND VACCINES DIRECTED AGAINST HUMAN ENTEROVIRUSES | April 2018 | September 2019 | Allow | 17 | 1 | 1 | Yes | No |
| 15782980 | METHOD OF DETECTING AND/OR IDENTIFYING ADENO-ASSOCIATED VIRUS (AAV) SEQUENCES AND ISOLATING NOVEL SEQUENCES IDENTIFIED THEREBY | October 2017 | August 2019 | Allow | 22 | 1 | 1 | Yes | No |
| 15728460 | INFLAMMASOME ACTIVATORS AND METHODS OF USE TO TREAT TUMORS | October 2017 | May 2020 | Allow | 31 | 2 | 1 | Yes | No |
| 15633906 | METHOD OF DETECTING AND/OR IDENTIFYING ADENO-ASSOCIATED VIRUS (AAV) SEQUENCES AND ISOLATING NOVEL SEQUENCES IDENTIFIED THEREBY | June 2017 | April 2019 | Allow | 22 | 1 | 2 | Yes | No |
| 15584674 | A METHOD OF DETECTING AND/OR IDENTIFYING ADENO-ASSOCIATED VIRUS (AAV) SEQUENCES AND ISOLATING NOVEL SEQUENCES IDENTIFIED THEREBY | May 2017 | September 2019 | Allow | 29 | 2 | 2 | Yes | Yes |
| 15232736 | CONSTRAINED IMMUNOGENIC COMPOSITIONS AND USES THEREFOR | August 2016 | February 2020 | Allow | 42 | 2 | 2 | Yes | Yes |
| 15172947 | Vaccine and Therapeutic Delivery System | June 2016 | September 2017 | Allow | 15 | 1 | 1 | Yes | No |
| 15035793 | HIV-1 ENV DNA Vaccine Plus Protein Boost Delivered by EP Expands B- and T-Cell Response and Neutralizing | May 2016 | July 2020 | Abandon | 50 | 13 | 1 | No | No |
| 14604215 | VACCINE AND THERAPEUTIC DELIVERY SYSTEM | January 2015 | November 2017 | Allow | 33 | 2 | 1 | Yes | No |
| 14402495 | Antigens and Vaccines Directed Against Human Enteroviruses | November 2014 | March 2018 | Allow | 40 | 3 | 1 | Yes | Yes |
| 14391904 | BISMUTH-CONTAINING CONCENTRATION AGENTS FOR MICROORGANISMS | October 2014 | February 2018 | Allow | 40 | 4 | 1 | No | No |
| 14124706 | PURIFICATION OF BIOLOGICAL PRODUCTS BY CONSTRAINED COHYDRATION CHROMATOGRAPHY | April 2014 | September 2016 | Allow | 33 | 2 | 1 | Yes | No |
| 14129613 | MODIFIED FOOT AND MOUTH DISEASE VIRUS (FMDV) VP1 CAPSID PROTEIN | March 2014 | June 2016 | Allow | 29 | 1 | 1 | Yes | No |
| 14209921 | COMPOSITIONS AND METHODS FOR LIVE, ATTENUATED ALPHAVIRUS FORMULATIONS | March 2014 | July 2018 | Allow | 52 | 4 | 0 | No | No |
| 14207135 | HEPATITIS B VIRUS VACCINES | March 2014 | January 2016 | Allow | 22 | 1 | 1 | No | No |
| 14112388 | SAPOLEGINA PROTEIN IN FOR USE AS A MEDICAMENT | October 2013 | May 2015 | Allow | 19 | 2 | 0 | Yes | No |
| 14110214 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING INFLUENZA VIRUSES REPLICATION | October 2013 | July 2015 | Allow | 21 | 2 | 1 | No | No |
| 14004308 | ADJUVANT COMPOSITION CONTAINING CITRULLINE | September 2013 | March 2016 | Allow | 30 | 3 | 1 | Yes | No |
| 13977108 | Device and Method for Sampling Bodily Fluid for Medical Analytes in Ultra Low Concentrations | September 2013 | March 2016 | Allow | 33 | 2 | 1 | No | No |
| 13980392 | PVRL4 (Nectin4) is a Receptor for Measles Virus | July 2013 | March 2016 | Allow | 32 | 2 | 0 | Yes | No |
| 13979322 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | July 2013 | March 2020 | Allow | 60 | 6 | 2 | Yes | No |
| 13901392 | ORDERED FLAGELLIN ARRAY AS AN IMMUNOSTIMULANT | May 2013 | November 2015 | Allow | 29 | 2 | 1 | Yes | No |
| 13636596 | METHODS OF INCREASING EFFICIENCY OF VECTOR PENETRATION OF TARGET TISSUE | April 2013 | October 2016 | Allow | 48 | 2 | 1 | No | Yes |
| 13823735 | ACTIVATABLE TOXIN COMPLEXES COMPRISING A CLEAVABLE INHIBITORY PEPTIDE | March 2013 | February 2016 | Allow | 35 | 2 | 1 | Yes | No |
| 13668052 | PLASMINOGEN-ACTIVATING ANTIBODY, USE AND PRODUCING METHOD THEREOF AND AGENT INCLUDING THE SAME | November 2012 | March 2014 | Allow | 16 | 2 | 1 | No | No |
| 13530891 | BINDING MEMBERS FOR HUMAN CYTOMEGALOVIRUS | June 2012 | January 2016 | Allow | 43 | 4 | 0 | Yes | No |
| 13501371 | INFECTIOUS CLONES OF TORQUE TENO VIRUS | June 2012 | July 2014 | Allow | 28 | 1 | 1 | Yes | No |
| 13499697 | METHOD, KIT, PLASMID AND COMPOSITION FOR INDUCING AN IMMUNE RESPONSE TO DENGUE VIRUS, ON THE BASIS OF DNA AND CHIMERIC VIRUS VACCINES | June 2012 | May 2019 | Allow | 60 | 7 | 1 | Yes | Yes |
| 13378391 | RECOMBINANT RSV VACCINES | December 2011 | June 2016 | Allow | 54 | 3 | 1 | Yes | No |
| 13319813 | PEPTIDIC ANTIGEN THAT INDUCES ANTIBODY RECOGNIZING THREE-DIMENSIONAL STRUCTURE OF HIV AND METHOD FOR SYNTHESIZING SAME | November 2011 | April 2015 | Allow | 41 | 2 | 1 | Yes | No |
| 12937981 | COMBINATION OF MAL AND CADMI MARKERS FOR HPV INDUCED INVASIVE CANCERS AND THEIR HIGH-GRADE PRECURSOR LESIONS | January 2011 | December 2015 | Allow | 60 | 3 | 1 | Yes | No |
| 12699340 | SYSTEMS AND METHODS FOR IDENTIFYING REPLIKIN SCAFFOLDS AND USES OF SAID REPLIKIN SCAFFOLDS | February 2010 | September 2015 | Allow | 60 | 4 | 2 | Yes | No |
| 11275842 | CULTURING CIRCULAR SSDNA VIRUSES FOR THE PRODUCTION OF VACCINES | January 2006 | April 2007 | Allow | 14 | 1 | 1 | No | No |
| 11170056 | INFECTIOUS BURSAL DISEASE VIRUS (IBDV) VARIANT FROM GEORGIA | June 2005 | March 2007 | Allow | 21 | 2 | 2 | No | No |
| 11122373 | FBL2-SPECIFIC AGENTS AS MODULATORS OF FLAVIVIRIDAE RNA REPLICATION | May 2005 | December 2006 | Allow | 19 | 3 | 1 | No | Yes |
| 10990204 | ESCAPE MUTANTS OF NEWCASTLE DISEASE VIRUS AS MARKER VACCINES | November 2004 | September 2005 | Allow | 10 | 1 | 0 | No | No |
| 10826929 | DNA VACCINE EXPRESSING HA1 OF EQUINE-2 INFLUENZA VIRUS | April 2004 | March 2007 | Allow | 35 | 3 | 0 | No | No |
| 10807194 | GENETICALLY BIOTINYLATED RECOMBINANT ANTIBODY IN IMMUNOFILTRATION ASSAY BY LIGHT ADDRESSABLE POTENTIOMETRIC SENSOR FOR IDENTIFICATION OF VENEZUELAN EQUINE ENCEPHALITIS VIRUS | March 2004 | August 2007 | Allow | 40 | 2 | 0 | No | No |
| 10729421 | IDENTIFICATION OF OLIGONUCLEOTIDES FOR THE CAPTURE, DETECTION AND QUANTITATION OF WEST NILE VIRUS | December 2003 | June 2006 | Allow | 30 | 1 | 1 | No | No |
| 10694247 | ORALLY-ADMINISTERED INTERFERON-TAU COMPOSITIONS AND METHODS | October 2003 | February 2007 | Allow | 40 | 2 | 0 | No | Yes |
| 10682739 | 12832, A NOVEL HUMAN KINASE-LIKE MOLECULE AND USES THEREOF | October 2003 | December 2006 | Allow | 38 | 2 | 0 | No | No |
| 10654737 | METHOD FOR GENERATING INFLUENZA VIRUSES AND VACCINES | September 2003 | October 2005 | Allow | 25 | 1 | 0 | No | No |
| 10608029 | ATTENUATED FLAVIVIRUS STRAINS CONTAINING A MUTATED M-ECTODOMAIN AND THEIR APPLICATIONS | June 2003 | September 2006 | Allow | 39 | 1 | 2 | Yes | No |
| 10459155 | IMMUNIZATION AGAINST FLAVIVIRUS | June 2003 | January 2006 | Allow | 31 | 2 | 0 | No | Yes |
| 10388327 | ALPHAVIRUS RNA REPLICON SYSTEMS | March 2003 | February 2007 | Allow | 47 | 2 | 0 | No | No |
| 10354606 | COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF EPIZOOTIC CATARRHAL ENTERITIS IN FERRETS | January 2003 | January 2006 | Abandon | 35 | 2 | 1 | No | No |
| 10231405 | IN VITRO ACTIVITY ASSAY FOR HUMAN HEPATITIS B VIRUS (HBV) DNA POLYMERASE, AND ITS USE FOR SCREENING FOR INHIBITORS OF HBV DNA POLYMERASE | August 2002 | September 2005 | Allow | 37 | 3 | 0 | Yes | No |
| 10049316 | PROTECTIVE ANTIGEN OF EPSTEIN BARR VIRUS | February 2002 | September 2005 | Allow | 43 | 2 | 2 | Yes | Yes |
| 09884481 | METHOD FOR EXPRESSING AND PURIFYING PROTEINS USING BUDDED BACULOVIRUS | June 2001 | January 2006 | Allow | 55 | 6 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SALVOZA, M FRANCO G.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 55.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner SALVOZA, M FRANCO G works in Art Unit 1672 and has examined 63 patent applications in our dataset. With an allowance rate of 95.2%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.
Examiner SALVOZA, M FRANCO G's allowance rate of 95.2% places them in the 84% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by SALVOZA, M FRANCO G receive 2.56 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by SALVOZA, M FRANCO G is 38 months. This places the examiner in the 29% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +4.0% benefit to allowance rate for applications examined by SALVOZA, M FRANCO G. This interview benefit is in the 27% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 25.7% of applications are subsequently allowed. This success rate is in the 41% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 51.6% of cases where such amendments are filed. This entry rate is in the 78% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 85.7% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 1.6% of allowed cases (in the 72% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 10.0% of allowed cases (in the 89% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.